We are live on ! Find out more
ARQT icon

Arcutis Biotherapeutics
ARQT

102 hedge funds and large institutions have $1.19B invested in Arcutis Biotherapeutics in 2021 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 40 increasing their positions, 25 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

525% more call options, than puts

Call options by funds: $4.36M | Put options by funds: $698K

60% more repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 25

53% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 15

25% more funds holding in top 10

Funds holding in top 10: 4 → 5 (+1)

9% more funds holding

Funds holding: 94 → 102 (+8)

2.95% less ownership

Funds ownership: 93.51% → 90.57% (-2.9%)

12% less capital invested

Capital invested by funds: $1.35B → $1.19B (-$160M)

Holders
102
Holders Change
+8
Holders Change %
+8.51%
% of All Funds
1.78%
Holding in Top 10
5
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+25%
% of All Funds
0.09%
New
23
Increased
40
Reduced
25
Closed
15
Calls
$4.36M
Puts
$698K
Net Calls
+$3.67M
Net Calls Change
+$324K

Top Buyers

1
Point72 Asset Management
Point72 Asset Management
Connecticut
+$12.9M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$7.56M
3
Ensign Peak Advisors
Ensign Peak Advisors
Utah
+$6.37M
4
State Street
State Street
Massachusetts
+$5.2M
5
PCH
Polar Capital Holdings
United Kingdom
+$3.52M

Top Sellers

1
FM
Frazier Management
Washington
-$59.4M
2
VC
Vivo Capital
California
-$8.75M
3
Marshall Wace
Marshall Wace
United Kingdom
-$4.35M
4
SAM
Sectoral Asset Management
Quebec, Canada
-$3.39M
5
MS
Maven Securities
Jersey
-$3.29M
Name Holding Trade Value Shares
Change 		Change in
Stake
FM
1
Frazier Management
Washington
$230M -$59.4M -2,108,558 -20%
Fidelity Investments
2
Fidelity Investments
Massachusetts
$206M -$2.98M -105,709 -1%
O
3
OrbiMed
New York
$166M – – –
BlackRock
4
BlackRock
New York
$116M +$1.31M +46,661 +1%
BCLSI
5
Bain Capital Life Sciences Investors
Massachusetts
$109M – – –
Vanguard Group
6
Vanguard Group
Pennsylvania
$40.8M -$994K -35,294 -2%
State Street
7
State Street
Massachusetts
$31.5M +$5.2M +184,500 +19%
T. Rowe Price Associates
8
T. Rowe Price Associates
Maryland
$25.2M +$7.56M +268,537 +41%
Wells Fargo
9
Wells Fargo
California
$24.5M +$602K +21,388 +2%
Point72 Asset Management
10
Point72 Asset Management
Connecticut
$24.5M +$12.9M +457,100 +104%
SAM
11
Sectoral Asset Management
Quebec, Canada
$20.7M -$3.39M -120,185 -14%
OFM
12
Omega Fund Management
Massachusetts
$17M – – –
Franklin Resources
13
Franklin Resources
California
$15.7M -$2.18M -77,280 -12%
PBPIA
14
Pivotal bioVenture Partners Investment Advisor
California
$15.5M – – –
Geode Capital Management
15
Geode Capital Management
Massachusetts
$13M +$1.22M +43,209 +10%
Citadel Advisors
16
Citadel Advisors
Florida
$12M -$308K -10,944 -2%
VC
17
Vivo Capital
California
$11.8M -$8.75M -310,785 -42%
Ensign Peak Advisors
18
Ensign Peak Advisors
Utah
$10.8M +$6.37M +226,013 +132%
American Century Companies
19
American Century Companies
Missouri
$10.3M +$23.2K +824 +0.2%
Ameriprise
20
Ameriprise
Minnesota
$9.69M +$1.06M +37,677 +12%
Northern Trust
21
Northern Trust
Illinois
$7.92M +$656K +23,285 +9%
N
22
Nuveen
North Carolina
$7.2M +$1.15M +40,838 +18%
Axa
23
Axa
France
$6.64M +$530K +18,816 +8%
ACM
24
Altium Capital Management
New York
$6.31M +$3.31M +117,352 +103%
Morgan Stanley
25
Morgan Stanley
New York
$6.18M +$2.84M +100,961 +80%
1
2 3 4 5

ARQT Hedge Fund Activity: Q2 2021 in Review

102 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Arcutis Biotherapeutics (ARQT) for Q2 2021, worth a combined $1.19B — down 12% from $1.35B a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new ARQT positions and 15 closed out — a net gain of 8 holders — while 40 added to existing stakes and 25 trimmed.

The largest buyer was Point72 Asset Management, adding an estimated $12.9M. The largest seller was Frazier Management, cutting an estimated $59.4M.

  • 102 institutional investors held Arcutis Biotherapeutics (ARQT) as of Q2 2021, up from 94 in Q1 2021.
  • Funds reported $1.19B of Arcutis Biotherapeutics stock for Q2 2021, down 12% quarter-over-quarter.
  • 23 funds opened new Arcutis Biotherapeutics positions in Q2 2021 and 15 closed out, a net change of +8 holders.
  • The largest Arcutis Biotherapeutics buyer in Q2 2021 was Point72 Asset Management, an estimated $12.9M added.
  • The largest Arcutis Biotherapeutics seller in Q2 2021 was Frazier Management, an estimated $59.4M sold.

Based on aggregated 13F filings for Q2 2021.